| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.45 | 0.01 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |